RxDoctor Payments Data

Chirag Shah, DO

Cardiovascular Disease · Monroe, NJNPI 1225257199

Payments from drug & device makers

$10,724in general payments, 2019–2025

Across 323 payments — averaging $33.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Global Services, LLC$3K
  • Impulse Dynamics (USA) Inc.$687
  • Johnson & Johnson$622
  • Merck$562
  • AstraZeneca$518
  • Cvrx, Inc.$486
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$2,60024%
  • Travel & lodging$1,21911%
  • Food & beverage$6,85364%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,724 in reported general payments places this provider in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$464,966
Medicare patients
1,797
Services billed
5,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban420$541,739
XareltoRivaroxaban122$139,460
MultaqDronedarone Hcl81$138,877
EntrestoSacubitril/Valsartan65$91,286
FarxigaDapagliflozin Propanediol44$47,468
Repatha SureclickEvolocumab36$41,829
JardianceEmpagliflozin20$29,616
VascepaIcosapent Ethyl15$11,686
BrilintaTicagrelor13$9,542
Rosuvastatin Calcium422$6,382
Metoprolol Succinate313$5,526
Atorvastatin Calcium475$5,422
Ezetimibe94$3,354
Midodrine Hcl12$2,668
Metoprolol Tartrate265$2,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$169$541,739420 claims
Johnson & JohnsonXarelto$622$139,460122 claims
Sanofi-aventis U.S. LLCMultaq$153$138,87781 claims
NovartisEntresto$403$91,28665 claims
AstraZenecaFarxiga, Brilinta$518$57,01157 claims
Boehringer IngelheimJardiance$149$29,61620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Monroe

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →